If you are a woman in 2026, you live in a low hum of health advice. Have children, the birthrate is falling. But also, it is fine not to have them, because your worth isn’t measured in babies. But as a backup plan, consider freezing your eggs. Track your cycle. “Balance” your hormones. Take hormone therapy. Avoid hormone therapy. Walk more. Lift weights. Sleep better. Get off your phone. On and on and on. If you opened your inbox or Instagram between meetings today, you probably saw a version of at least three of those.
Some of this is helpful, some of it is opportunistic marketing, forever inventing new things for women to fix and buy. A fair amount is built on research that, for much of the last century, included few women and rarely asked how female biology might differ from male biology. Aging science has often treated a male body as the default. Only in the last decade have researchers begun to map how men and women age differently in a systematic way.1–3 As that work has unfolded, one organ keeps coming up as unusually important for women’s aging: the ovary.
Any reader worth her salt is rolling her eyes right now. Obviously the ovary is important to women’s aging, it is one of the few organs that clearly differ between male and female bodies. But science has mostly treated ovaries as baby-making equipment, relevant when a woman wants a pregnancy and an afterthought once her periods stop. From puberty onward, though, the ovaries are doing far more than releasing eggs. They send pulses of estrogen and progesterone to the brain, heart, bones, and immune system. And somewhere around 50, they fall quiet. Menopause is usually framed as the end of fertility, but that shutdown also marks a turn in risk for dementia, heart disease, osteoporosis, and other conditions – a turn that is even sharper for women who go through menopause unusually early.
Seen this way, aging for women is far more than wrinkles, step counts or the infamous “biological clock”. It is tightly linked to the life history of the ovaries, from their maturation in puberty to their silence after menopause. If you care about whether women reach old age with their memory, mobility, and independence intact, ovarian aging belongs at the center of the conversation. And if ovarian timing matters that much, the real question is whether changing when and how menopause occurs could change the entire trajectory of women’s aging.
Living longer, feeling older
Public health data have been consistent for decades: women outlive men almost everywhere in the world. In some countries the gap in average lifespan approaches ten years.4 The catch is that many of those extra years are spent with more frailty, disability, osteoporosis, dementia, and other chronic conditions. Researchers call this the male–female health survival paradox.5–6
A few broad biological quirks seem to feed into it. Genetically, women carry two copies of the X chromosome, with built in redundancy for thousands of genes. Men’s single X is more exposed to harmful mutations acquired over a lifetime, an idea sometimes called the “unguarded X” hypothesis.7 Women’s immune systems tend to be stronger and age more slowly, which helps them survive infections but also raises the risk of autoimmune disease.8 And when scientists use DNA methylation and other markers to build “biological aging clocks,” men usually come out older than women of the same chronological age. But the hormonal changes of menopause are themselves associated with an acceleration in women’s biological aging.9,10
All of this loops back to what the ovaries are doing. For roughly four decades, they secrete estrogen and progesterone in carefully timed pulses. Those hormones do far more than prepare the uterus for pregnancy. They talk to the brain, the cardiovascular system, bone, fat, and immune cells. When ovarian function declines and then stops, that hormonal conversation changes abruptly.
You can think of it this way: men tend to age along a relatively smooth curve, while women age in chapters. The same ovarian system that supports pregnancy and early life survival seems to set women up for a different pattern of vulnerability later, once that system winds down. This is the starting point for rethinking menopause as far more than the end of fertility.
How an ovary gets old
Most of the story we tell about ovarian aging revolves around one number: egg count. You are born with one to two million oocytes and by puberty only a few hundred thousand remain. Every month, more are lost. When the egg reserve falls below a certain threshold, cycles become erratic and then stop.
Image by Esin Deniz via Adobe Stock
That picture is not wrong, but it is incomplete. It treats the ovary like a warehouse with dwindling stock. In reality, it is a small but powerful organ with distinct neighborhoods – different kinds of tissues that age, and in some ways fall apart, long before the last egg is gone.
Roughly speaking, the ovary has two main components. The outer layer, the cortex, is where follicles live. Each follicle is a tiny pocket that holds an immature egg surrounded by helper cells and, as it grows, can fill with fluid. Deeper inside is the medulla, packed with blood vessels and connective tissue. Over time, follicles grow and either release an egg or quietly break down. The ovary, as a whole, is held together by a mesh of structural proteins and stromal cells, threaded with nerves and capillaries. Whether a follicle develops properly depends not just on the chromosomes inside the egg, but also on how stiff the surrounding tissue is, how much blood reaches it, and what mix of hormones and growth factors nearby cells are sending its way. In this context, an egg is only as healthy as the tissue around it.
With age, that environment shifts. In mouse and human ovaries, the tissue around follicles shows thicker, denser, more scar-like material, all classic signs of fibrosis.11 Collagen builds up, the cortex hardens. Follicles then sit in a physical environment that makes it harder for them to expand and for an egg to be released at ovulation. Fibrosis can also warp hormone gradients and pinch the tiny vessels that feed follicles. Studies comparing young and old ovaries find that sympathetic nerves around follicles become more abundant with age, and that stromal cells such as fibroblasts shift toward inflammation and scarring – changes that may mark declines in follicle health and overall ovarian function.12
Taken together, these tissue-level changes look less like harmless background and more like active drivers of ovarian aging. The striking part is that some of them appear at least partly reversible. In one experiment, researchers delivered the anti-fibrotic drug pirfenidone, already approved for pulmonary fibrosis, to “reproductively old” mice. Within weeks, ovarian collagen decreased and more than half of previously anovulatory animals ovulated again; their eggs could be fertilized and grown to blastocysts in vitro.11 Shorter treatment in slightly younger mice also reduced fibrosis and increased the number of eggs released, without changing the ovaries in young controls.
At the moment, no one is prescribing pirfenidone as a fertility drug for humans as its effects on ovarian aging have only been shown in mice. But findings like this support a central idea: the ovary is an organ whose aging may one day be modulated, not just endured. If that is true, the next question is what happens to the rest of the body when the ovarian clock speeds up – or when it slows down.
What happens when the ovaries go quiet
Clinically, menopause is defined as twelve months without a period. Biologically, it’s a major transition for several organ systems simultaneously. There’s also a long list of familiar symptoms – hot flashes, sleep disruption, mood changes, vaginal dryness, shifts in body composition – that can make everyday life feel very different. The menopause-related changes in the brain and cardiovascular system, however, are most strongly tied to long-term outcomes: dementia risk, heart disease, and ultimately how long and how well people live.
The brain is dense with estrogen receptors, especially in regions that regulate memory, mood, sleep, and body temperature. From puberty onward, these brain regions have been running in the background on a relatively steady stream of ovarian estrogen. When that signal drops, both brain metabolism and structure shift. Longitudinal imaging studies find that women moving through menopause show reduced glucose metabolism and gray matter volume in specific regions, along with more amyloid deposition, compared with age-matched men and premenopausal women.13–16 Some of these patterns resemble early changes seen in Alzheimer’s disease.
Most women experiencing menopause report hot flashes and night sweats. Frequent vasomotor symptoms like these have been linked to small vascular lesions in the brain and to blood-based biomarkers associated with future dementia risk.17 For many women, cognition stabilizes after the transition. Still, women overall are more likely than men to develop dementia in later life.
The cardiovascular system also pivots. Before menopause, women on average develop heart disease about ten years later than men, a gap often attributed to estrogen’s protective effects on blood vessels. After menopause, blood pressure and LDL cholesterol tend to rise, arteries stiffen, and women’s risk of heart disease begins to catch up.18
Timing matters here. The earlier the ovaries fall silent, the steeper the consequences. Women who go through surgical menopause, having both ovaries removed, show faster cognitive decline, more Alzheimer’s type pathology, and higher dementia risk than women with intact ovaries.19 Premature ovarian insufficiency and very early natural menopause, before about 40, are linked to higher overall and cardiovascular mortality and more osteoporosis.20
Natural menopause at the typical age, around 51, still marks an uptick in risk, but how big that jump is depends heavily on midlife blood pressure, weight, smoking, and glucose control. Put together, these patterns have led some researchers to a blunt question: if ovarian shutdown is such a powerful pivot, do women whose ovaries keep working longer actually live longer?
When the ovaries take their time
Across multiple cohorts, the answer appears to be yes – modestly but consistently. In the Women’s Health Initiative, a study of more than 16,000 women, those with a reproductive lifespan longer than 40 years (from first period to menopause) had about 13 percent higher odds of reaching age 90 than those with less than 33 reproductive years, even after accounting for smoking, BMI, and other factors.21 A Swedish twin cohort found that women with 40 or more reproductive years had lower all-cause mortality and about 0.8 extra years of life than those with 34 or fewer.22
Cardiovascular outcomes point the same way. In a Chinese cohort, each additional year of reproductive lifespan was associated with about a 2 percent lower risk of cardiac death.23 Other work links later natural menopause and longer reproductive span with longer telomeres in white blood cells and “younger” brain-age metrics on MRI.24,25
The flip side is just as telling. Analyses of the National Health and Nutrition Examination Survey (NHANES), a long-running U.S. health survey, show that women with premature menopause and very short reproductive lifespans have higher mortality and shorter life expectancy.26 Removing both ovaries before natural menopause (surgical menopause) amplifies that risk further, especially for dementia and cardiovascular disease, unless women receive hormone therapy tailored to their age and health history.
These are correlations, not guarantees, and the effect sizes for any one woman are small. No one earns a decade of extra life from a slightly later last period. Taken together, though, the signal is hard to ignore: women whose ovaries function for longer tend to have longer and healthier lives.
Under the hood, genetics does a lot of the steering. Twin and family studies estimate that 40 to 50 percent of the variation in age at natural menopause is heritable; mothers, daughters, and sisters show parallel patterns.27,28 Even brothers of women with later menopause have a survival advantage.29 Large genome-wide association studies link later menopause to variants in DNA repair pathways, FSH signaling, and IGF1 and mTOR pathways – the same circuits implicated in cancer, cardiovascular disease, and lifespan more broadly.30,31 In animal experiments, transplanting young ovaries into older mice extends the older animals’ lifespan, even when the grafted ovaries cannot produce eggs, which suggests that ovarian hormones themselves, not just fertility, are protective.32–33
Seen in that light, the infamous “biological clock” looks less like a timer counting down to the last viable egg and more like a gauge of how long the ovaries keep sending protective signals to the rest of the body. That reframing leads directly to the question driving a new wave of research: if later menopause and longer ovarian function are linked to better outcomes, can we safely nudge that timing?
Can we safely delay menopause?
Image design by Kelly Rich, MS, CGC, PhD via Canva
No one is promising pills that will keep 70-year-olds ovulating. But several experimental approaches are circling the same target: slowing ovarian aging by preserving follicles and easing the tissue-level changes that eventually tip the ovary into menopause.
One line of work targets fibrosis. The pirfenidone experiments in mice suggest that reducing ovarian scarring can restore ovulation in reproductively old animals.11 Researchers are now testing other anti-fibrotic strategies in animal models to see whether easing stiffness and collagen buildup can not only prompt ovulation but also shift hormone profiles and delay the final shutdown.
Another strategy uses anti-Müllerian hormone (AMH), produced by growing follicles, which normally acts as a brake on the activation of the primordial follicle pool. High AMH levels keep more follicles in reserve; low levels allows more follicles to move into active growth, where most are eventually lost.34 Pharmaceutical AMH analogs are currently being tested in animals to see whether pressing harder on that AMH brake can reduce the number of eggs lost each cycle and extend the ovarian reserve.
Then there are the drugs that have become darlings of the aging research world. In middle-aged mice, chronic low-dose metformin – a diabetes medication that has attracted interest as a possible geroprotective – increased the number of primordial and primary follicles, improved estrous cycles and estradiol levels, reduced oxidative damage, and upregulated the longevity-linked protein SIRT1 in the ovary, consistent with delayed ovarian aging and a healthier microenvironment.35 mTOR inhibitors are on the list too. mTOR is one of the body’s main nutrient-sensing switches; dialing it down in animals extends lifespan and appears to preserve ovarian reserve for longer. A clinical trial at Columbia University is now testing rapamycin, an mTOR-inhibiting immunosuppressant that extends lifespan in mice, in women aged 35 to 45 to see whether it changes measures of ovarian reserve. Alongside these pathway-targeting drugs, some fertility clinics offer a range of so-called “ovarian rejuvenation” procedures. These include injecting platelet-rich plasma directly into the ovaries, delivering stem-cell-based products, and even transferring mitochondria into oocytes.36 Some small studies report changes in surrogate markers such as AMH levels, follicle count, or oocyte yield after these procedures, but so far they have not consistently translated into higher rates of healthy embryos, ongoing pregnancy, or live birth.
All of this work is early and still mostly proof of concept, and we must be careful about how we read it. Most studies are in rodents and human trials are just beginning. At a deeper level, the field is starting to sort out what it would mean to truly slow ovarian aging, rather than simply squeeze a few more eggs out of an already stressed organ. Much of the most interesting work now zeroes in on the ovarian microenvironment – fibrosis, blood flow, inflammatory signaling, and nutrient-sensing pathways like mTOR – asking whether easing scarring or dialing down overactive growth signals can preserve existing follicles and maintain hormone production for longer. That is a very different goal from transiently “activating” dormant follicles to boost egg retrieval in the short term, which may actually accelerate the depletion of the ovarian reserve.
No one knows what the long-term trade-offs will be, and there are real biological reasons to be cautious. Later natural menopause is associated with a slightly higher risk of breast and endometrial cancer, likely due to more years of estrogen exposure, even as it links to lower cardiac death and slightly longer life overall.37 Extending ovarian function pharmacologically could sharpen that tension. Beyond this, keeping the ovaries online longer might also mean more years of managing contraception, with unclear implications for pregnancy risk at older ages.
Most women alive today will never take pirfenidone for ovarian fibrosis or enroll in a rapamycin trial. But the emerging science still matters. It shifts menopause from a mysterious cliff to a biological process with moving parts – some of which might, one day, be adjustable. And it sharpens the picture of what “aging well” means for women right now, and how paying attention to ovarian cues can pay off.
A framework for aging, with ovaries in mind
By now it should be clear there is no master supplement stack or perfect hormone regimen. What the data do offer is a way to read your own history and the flood of advice through an ovarian lens. Here are five filters to help organize it.
Treat reproductive timing as a health signal, not just a fertility alarm. Age at first period, cycle regularity, age at menopause, and total reproductive lifespan carry information about later risk for cardiovascular disease, osteoporosis, and dementia, especially when menopause arrives unusually early. They belong in the same mental bucket as family history or blood pressure – cues for monitoring and topics to raise with your clinician.
Protect the midlife pivot. For most women, the late 40s and early 50s are when ovarian function winds down and curves for heart disease, bone loss, and cognitive changes start to steepen. That is why timing matters so much for things like hormone therapy, blood-pressure and lipid control, GLP-1 drugs, and mood treatment: the same intervention has different implications depending on its timing.
See weight and metabolism in terms of future muscle, bone, and brain. Weight-loss and glucose-lowering drugs can dramatically improve cardiometabolic markers, especially for women entering menopause with obesity or diabetes. At the same time, midlife is when women have accelerated loss of lean mass and bone density, so approaches that decrease fat at the expense of muscle and skeleton needs to be understood in terms of trade-offs.
Be skeptical of one-size-fits-all longevity hacks. Intermittent fasting protocols, supplement stacks, and mTOR- or NAD+-targeting regimens were often built and tested in male animals. For women, especially those who are premenopausal or recently menopausal, that means approaching these interventions as hypotheses to test in your own body, not universal rules.
Think in stages, not lifelong rules. The levers that matter most shift over time: building peak bone and muscle in youth, recognizing cycle patterns and inflammatory conditions in the reproductive years, focusing on vascular health, sleep, mood, and time-sensitive hormone decisions around menopause, then emphasizing strength, balance, cognition, and social connection later on. The ovaries eventually retire, but the architecture they helped build is what you are living in, and different parts of that structure will need attention at different times.
Centering ovaries in the future of women’s health
For most of medical history, the ovaries were treated as switches for fertility: on, then off. The rest of women’s aging was filed under “general medicine” or (let’s be honest) “mystery”. The emerging picture is less dimmer-switch, more master control room. The ovaries are wired into the brain, heart, immune system, and skeleton, sending signals that shape how the whole system weathers time.
We are only just starting to see what it might mean to adjust that wiring on purpose. Anti-fibrotic drugs, AMH analogs, and rapamycin trials are early, cautious attempts to investigate whether we can delay or soften ovarian shutdown without trading hot flashes for a different kind of disaster. So far, the cutting edge looks exciting, but it is also small, experimental, and a long way from anything women should be trying on their own outside carefully run clinical trials.
Meanwhile, the boring stuff remains fundamentally powerful. Controlling blood pressure, building and keeping muscle, not smoking, sleeping like it matters, taking statins or GLP-1s when they’re indicated – these are still the most reliable levers for extending healthy life, including for women whose ovaries are coasting toward, or already well past, menopause.
If ovaries are the major architects of health in female bodies, the task now is to fund, run, and take seriously the science that treats those architects as more than baby makers. That means clinical trials which include women in real numbers, basic research that does not assume the male body is the default setting, and policy that treats menopause as a systemic transition rather than a punch line. Developing real therapeutic options will require adequately-powered randomized trials with standardized protocols and hard endpoints (not just AMH or follicle counts), long-term safety data on cancer and metabolic risk, and regulatory frameworks that clearly distinguish experimental procedures from established care.
We are still early in this story, but the shift is already profoundly hopeful. A generation ago, menopause was something women were expected to endure in silence. Today, we can point to pathways, trials, and concrete levers that link ovarian timing to how long our brains, hearts, and bones stay resilient. Paying attention to ovaries is not about worshipping fertility. It is about finally centering an organ that has been steering women’s health all along, and using that insight to design better research, better treatments, and better odds of staying sharp, strong, and independent into old age. The more precisely we understand what ovaries are doing, the more leverage we have to turn added years of life into years of health.
References
1. Hagg, S. & Jylhava, J. Sex differences in biological aging with a focus on human studies. Elife 10, doi:10.7554/eLife.63425 (2021).
2. Austad, S. N. & Fischer, K. E. Sex Differences in Lifespan. Cell Metab 23, 1022-1033, doi:10.1016/j.cmet.2016.05.019 (2016).
3. Sampathkumar, N. K. et al. Widespread sex dimorphism in aging and age-related diseases. Hum Genet 139, 333-356, doi:10.1007/s00439-019-02082-w (2020).
4. OECD. Which diseases affect men and women differently – and why this matters: Health at a Glance. (2025). <https://www.oecd.org/en/publications/health-at-a-glance-2025_8f9e3f98-en/full-report/which-diseases-affect-men-and-women-differently-and-why-this-matters_c7602de9.html>.
5. Gordon, E. H. et al. Sex differences in frailty: A systematic review and meta-analysis. Exp Gerontol 89, 30-40, doi:10.1016/j.exger.2016.12.021 (2017).
6. Arosio, B. & Picca, A. The biological roots of the sex-frailty paradox. Exp Gerontol 198, 112619, doi:10.1016/j.exger.2024.112619 (2024).
7. Marais, G. A. B. et al. Sex gap in aging and longevity: can sex chromosomes play a role? Biol Sex Differ 9, 33, doi:10.1186/s13293-018-0181-y (2018).
8. Calabro, A., Accardi, G., Aiello, A., Caruso, C. & Candore, G. Sex and gender affect immune aging. Front Aging 4, 1272118, doi:10.3389/fragi.2023.1272118 (2023).
9. Phyo, A. Z. Z. et al. Sex differences in biological aging and the association with clinical measures in older adults. Geroscience 46, 1775-1788, doi:10.1007/s11357-023-00941-z (2024).
10. Levine, M. E. et al. Menopause accelerates biological aging. Proc Natl Acad Sci U S A 113, 9327-9332, doi:10.1073/pnas.1604558113 (2016).
11. Umehara, T. et al. Female reproductive life span is extended by targeted removal of fibrotic collagen from the mouse ovary. Sci Adv 8, eabn4564, doi:10.1126/sciadv.abn4564 (2022).
12. Gaylord, E. A. et al. Comparative analysis of human and mouse ovaries across age. Science 390, eadx0659, doi:10.1126/science.adx0659 (2025).
13. Mosconi, L. et al. Sex differences in Alzheimer risk: Brain imaging of endocrine vs chronologic aging. Neurology 89, 1382-1390, doi:10.1212/WNL.0000000000004425 (2017).
14. Mosconi, L. et al. Menopause impacts human brain structure, connectivity, energy metabolism, and amyloid-beta deposition. Sci Rep 11, 10867, doi:10.1038/s41598-021-90084-y (2021).
15. Mosconi, L. et al. In vivo brain estrogen receptor density by neuroendocrine aging and relationships with cognition and symptomatology. Sci Rep 14, 12680, doi:10.1038/s41598-024-62820-7 (2024).
16. Raikes, A. C. et al. White matter microstructural and macrostructural profiles during midlife reveal sex differences between men and women at different menopausal stages. Sci Rep 15, 40312, doi:10.1038/s41598-025-24136-y (2025).
17. Thurston, R. C. et al. Menopausal vasomotor symptoms and plasma Alzheimer disease biomarkers. Am J Obstet Gynecol 230, 342 e341-342 e348, doi:10.1016/j.ajog.2023.11.002 (2024).
18. Merz, A. A. & Cheng, S. Sex differences in cardiovascular ageing. Heart 102, 825-831, doi:10.1136/heartjnl-2015-308769 (2016).
19. Bove, R. et al. Age at surgical menopause influences cognitive decline and Alzheimer pathology in older women. Neurology 82, 222-229, doi:10.1212/WNL.0000000000000033 (2014).
20. Podfigurna-Stopa, A. et al. Premature ovarian insufficiency: the context of long-term effects. J Endocrinol Invest 39, 983-990, doi:10.1007/s40618-016-0467-z (2016).
21. Shadyab, A. H. et al. Ages at menarche and menopause and reproductive lifespan as predictors of exceptional longevity in women: the Women's Health Initiative. Menopause 24, 35-44, doi:10.1097/GME.0000000000000710 (2017).
22. Li, X. et al. Association of life-course reproductive duration with mortality: a population-based twin cohort study. Am J Obstet Gynecol 227, 748 e741-748 e713, doi:10.1016/j.ajog.2022.06.053 (2022).
23. Chen, L. et al. Age at Menarche and Menopause, Reproductive Lifespan, and Risk of Cardiovascular Events Among Chinese Postmenopausal Women: Results From a Large National Representative Cohort Study. Front Cardiovasc Med 9, 870360, doi:10.3389/fcvm.2022.870360 (2022).
24. Steventon, J. J. et al. Menopause age, reproductive span and hormone therapy duration predict the volume of medial temporal lobe brain structures in postmenopausal women. Psychoneuroendocrinology 158, 106393, doi:10.1016/j.psyneuen.2023.106393 (2023).
25. Konishi, K. et al. Leukocyte telomere length and memory circuitry and cognition in early aging: Impact of sex and menopausal status. Horm Behav 165, 105631, doi:10.1016/j.yhbeh.2024.105631 (2024).
26. Xing, Z., Alman, A. C. & Kirby, R. S. Premature Menopause and All-Cause Mortality and Life Span Among Women Older Than 40 Years in the NHANES I Epidemiologic Follow-Up Study: Propensity Score Matching Analysis. J Womens Health (Larchmt) 32, 950-959, doi:10.1089/jwh.2023.0189 (2023).
27. Morris, D. H., Jones, M. E., Schoemaker, M. J., Ashworth, A. & Swerdlow, A. J. Familial concordance for age at natural menopause: results from the Breakthrough Generations Study. Menopause 18, 956-961, doi:10.1097/gme.0b013e31820ed6d2 (2011).
28. Murabito, J. M., Yang, Q., Fox, C., Wilson, P. W. & Cupples, L. A. Heritability of age at natural menopause in the Framingham Heart Study. J Clin Endocrinol Metab 90, 3427-3430, doi:10.1210/jc.2005-0181 (2005).
29. Smith, K. R. et al. Familial aggregation of survival and late female reproduction. J Gerontol A Biol Sci Med Sci 64, 740-744, doi:10.1093/gerona/glp055 (2009).
30. Ruth, K. S. et al. Genetic insights into biological mechanisms governing human ovarian ageing. Nature 596, 393-397, doi:10.1038/s41586-021-03779-7 (2021).
31. Zhang, L. et al. Joint Genome-Wide Association Analyses Identified 49 Novel Loci For Age at Natural Menopause. J Clin Endocrinol Metab 106, 2574-2591, doi:10.1210/clinem/dgab377 (2021).
32. Cargill, S. L., Carey, J. R., Muller, H. G. & Anderson, G. Age of ovary determines remaining life expectancy in old ovariectomized mice. Aging Cell 2, 185-190, doi:10.1046/j.1474-9728.2003.00049.x (2003).
33. Mason, J. B., Cargill, S. L., Anderson, G. B. & Carey, J. R. Transplantation of young ovaries to old mice increased life span in transplant recipients. J Gerontol A Biol Sci Med Sci 64, 1207-1211, doi:10.1093/gerona/glp134 (2009).
34. Pankhurst, M. W. A putative role for anti-Mullerian hormone (AMH) in optimising ovarian reserve expenditure. J Endocrinol 233, R1-R13, doi:10.1530/JOE-16-0522 (2017).
35. Qin, X. et al. Metformin prevents murine ovarian aging. Aging (Albany NY) 11, 3785-3794, doi:10.18632/aging.102016 (2019).
36. Eubanks, A. A., Goldman, K. N., Babayev, E., Duncan, F. E. & Widra, E. Influencing ovarian aging in reproductive medicine: promise, evidence, and unresolved questions. Fertil Steril 125, 387-398, doi:10.1016/j.fertnstert.2025.12.020 (2026).
37. Collaborative Group on Hormonal Factors in Breast, C. Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies. Lancet Oncol 13, 1141-1151, doi:10.1016/S1470-2045(12)70425-4 (2012).
Lifespan Magazine is proud to support medical research and the Lifespan Foundation
Last Updated: Aug 7, 2026 · 16 minute
